199 Rue Hélène Boucher
Castelnau-le-Lez 34170
France
33 4 11 93 76 67
https://www.nflbiosciences.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Ignacio Faus M.B.A., Ph.D. | CEO & Chairman | S.O. | S.O. | S.O. |
Mr. Bruno Lafont M.B.A., M.Sc. | Co-Founder, COO & Director | S.O. | S.O. | S.O. |
Mr. Guillaume Audema | Chief Financial Officer | S.O. | S.O. | S.O. |
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. The company's natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. NFL Biosciences SA was incorporated in 2006 and is based in Castelnau-le-Lez, France.
L’ISS Governance QualityScore de NFL Biosciences SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..